Maria Salazar Buys SpaceX and Berkshire Hathaway Shares

Rep. Maria Elvira Salazar’s latest disclosures put two of the market’s most recognizable billionaire brands in the same portfolio: Elon Musk’s SpaceX and Warren Buffett’s Berkshire Hathaway.

The Florida Republican reported purchasing SpaceX shares twice on August 12, with each transaction valued between $1,001 and $15,000, according to her Periodic Transaction Report filed with the House Clerk on September 9. SpaceX began trading publicly earlier this year under the ticker SPCX, giving congressional investors direct access to Musk’s private-company empire for the first time.

Salazar also bought Berkshire Hathaway Class B shares on August 7 in the same disclosed range. That followed two Berkshire purchases on July 28, one valued between $1,001 and $15,000 and another between $15,001 and $50,000. The transactions suggest a sustained allocation to the conglomerate rather than a one-off trade, though congressional disclosures do not reveal exact dollar amounts or the investor’s rationale.

The filing covered more than just marquee names. Salazar bought Merck shares in the $15,001-to-$50,000 range and Moderna shares for between $1,001 and $15,000 on August 19, the same day Moderna publicized positive Phase 3 results for a melanoma vaccine developed with Merck’s Keytruda. She also partially sold Moderna stock that day.

Other reported transactions included sales of Qualcomm shares on August 12 and August 19, along with an IBM sale on August 24. Chubb shares were sold on August 19, while the July filing showed sales of Carrier Global stock.

The timing matters for anyone attempting to mirror congressional activity. The SpaceX and Berkshire trades were disclosed 28 and 33 days after execution, respectively, illustrating the lag built into the STOCK Act reporting system. These are historical disclosures, not real-time signals, and the reported ranges can span tens of thousands of dollars.

Berkshire’s purchase also lands during a leadership transition. Greg Abel became chief executive at the start of 2026, while Buffett remains the company’s chairman, leaving investors to weigh the durability of Buffett’s investment framework against the new CEO’s capital-allocation decisions.